Scientific Advisory Board
We are delighted to announce our first ever Scientific Advisory Board (SAB). We are honoured to have exceptional experts in the area of neuroblastoma form this Committee who will be assessing the requests we receive for funding research projects. With their expertise, we will be able to ensure we fund the most promising meaningful research in line with our mission; developing better and safer treatments so all children diagnosed with neuroblastoma get the chance to grow up and lead a long and healthy life.
Professor Andy Pearson
Prof Andy Pearson is formerly a Cancer Research UK Professor of Paediatric Oncology, at the Institute of Cancer Research and the Royal Marsden Hospital NHS Trust. During a long and distinguished career, he helped establish and led many key groups in the paediatric oncology landscape both nationally and internationally. Prof Pearson authored the first international guidelines for the conduct of Phase I trials in children with cancer, and led the first paediatric Phase I study in the UK. He was the founding chair of International Society for Paediatric Oncology Europe Neuroblastoma Committee (SIOPEN) and the Chief Investigator of the BEACON Trial; the first ever randomised European study for children with refractory/relapsed neuroblastoma.
He has held many international positions of influence; including Executive membership of the Innovative Therapy for Children with Cancer Consortium (ITCC), Board membership of SIOPEN, Co-Chair of the International Neuroblastoma Risk Group Strategy (INRG), and membership of the Steering Committee of the multi-stakeholder ACCELERATE Platform. He has published over 350 scientific manuscripts.
He retired from clinical practice in May 2014 due to ill health. Prof Pearson is an eminent figure in the fields of drug development and neuroblastoma research and was awarded a Life Time Achievement Award from Advances in Neuroblastoma Research in 2016.
Associate Professor Juliet Gray
Dr. Juliet Gray is an Associate Professor in Paediatric Oncology at the Cancer Immunology Centre, University of Southampton. She leads a translational research group focused on novel antibody immunotherapies for neuroblastoma, including preclinical evaluation of novel combinational therapies as well as early phase clinical trials.
Dr. Gray’s specific research interests are in targeting anti-GD2 monoclonal antibodies, and immunomodulatory antibodies such as those targeting PD-1. She has developed the laboratory support and immune endpoint assays within the Southampton Experimental Cancer Medicine Centre, required to support early phase immunotherapy studies.
Dr. Gray was the UK Chief Investigator and member of the Trial Steering Committee for the SIOPEN Long Term Infusion of ch14.18 (anti-GD2) monoclonal antibody in children with relapsed/refractory neuroblastoma, and is the Chief Investigator of the first ever transatlantic neuroblastoma study to open in the UK – a multi-centre Phase I trial of 131-I mIBG therapy, Nivolumab and ch14.18/CHO in children with relapsed/refractory neuroblastoma.
Dr. Gray plays a key role in both UK and European neuroblastoma research; and is a member of the UK NCRI Childhood Cancer and Leukaemia Neuroblastoma subgroup, executive member of the European Neuroblastoma Research Network (SIOPEN), and member of the SIOPEN Immunotherapy Committee.
Dr Steve DuBois
Dr. DuBois is director of experimental therapeutics at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. He is a pediatric oncologist with an active clinical and translational research program focused on patients with advanced neuroblastoma and Ewing sarcoma. He conducts phase 1 and 2 clinical trials of novel targeted agents. His clinical practice focuses on providing outstanding team-based care for children and young adults with solid cancers. He also studies new biomarkers that improve current understanding of the biology of pediatric solid tumors and of the pharmacodynamic effects of targeted therapies.
Dr. DuBois has served on a number of national committees, including the Children’s Oncology Group (COG) Neuroblastoma Steering Committee, COG Bone Tumor Committee, COG Developmental Therapeutics Executive Committee, the American Society of Clinical Oncology (ASCO) Scientific Program Committee, and the US FDA Pediatric Oncology Drugs Advisory Committee (ODAC).